Tirzepatide / LY3298176 30mg Lyophilized Peptide Vial Supplier

Product Overview

Tirzepatide, also known as LY3298176, can be discussed as a 30mg lyophilized peptide vial project where documentation, batch consistency, sourcing transparency, and project-specific specifications are required. WUMO supports business-side evaluation, document checks, packaging planning, and supply discussions based on buyer qualification, destination market, and applicable import or distribution expectations.

WUMO does not provide medical guidance, personal-use information, product-use instructions, disease-related claims, or end-user outcome claims. All discussions are limited to qualified B2B sourcing, documentation review, and project feasibility.

Technical Snapshot

What WUMO Can Supply

• Tirzepatide / LY3298176 30mg lyophilized peptide vial supply for qualified B2B projects
• Peptide raw material review where appropriate for the sourcing path
• Custom fill quantity discussion, including 30mg/vial project review
• Neutral-label and private-label packaging support
• COA, HPLC, MS, SDS/MSDS, and batch traceability records where available
• Business-side sample evaluation, MOQ discussion, and lead time planning
• Documentation package discussion based on buyer requirements and destination market

Quality and Documentation

WUMO focuses on documentation-driven supply for B2B peptide projects. For Tirzepatide / LY3298176 30mg lyophilized peptide vial projects, available quality documentation may include batch-specific COA, HPLC report, MS report, SDS/MSDS, and traceability information. Documentation scope may vary by batch, project type, packaging arrangement, buyer requirements, and destination market.

Custom Lyophilized Vial Options

• 30mg/vial project discussion
• Custom fill quantity review
• Vial and stopper configuration discussion
• Neutral-label presentation
• Private-label or OEM packaging support
• Outer box or carton format
• Batch coding and traceability format
• Documentation package requirements
• MOQ, lead time, and phased delivery planning

Buyer Qualification Checklist

• Company name and business type
• Target market or destination country
• Intended business use
• Required form: raw material, 30mg lyophilized vial, private-label vial, or other project format
• Required documentation package
• Requested fill quantity and estimated order volume
• Packaging preference: neutral label or private label
• Import, distribution, or handling authorization where applicable
• Required timeline and business-side sample evaluation needs
• Quotation unit preference: USD/g, USD/vial, USD/box, or project-based quote

Related B2B Guide

For a structured procurement review path, read the Tirzepatide 30mg B2B Sourcing Guide.

Available fill specifications

Tirzepatide is filled to several vial specifications. The fill amount is the only difference between them — identity, purity and batch documentation come from the same bulk material, so a buyer comparing sizes is comparing packaging, not quality.

State the required fill amount and vial count at inquiry stage; alternative fill specifications can be quoted as a project.

Current batch documentation

The 30mg specification is currently documented against bulk batch WM-U7U0-TR. Purity and identity on that certificate were determined on the bulk peptide used for filling; the fill amount is stated against the filling record. Those are two different kinds of evidence and the certificate says so on its face.

The batch certificate can be downloaded from our document centre. Documents for the specific lot you are quoted are issued against that lot — confirm the batch on the certificate matches the batch on the offer before comparing suppliers. Our annotated walkthrough of a batch certificate explains which figures on a COA are specifications, which are measurements, and which are neither.

Compliance Note

Tirzepatide / LY3298176 is offered for laboratory research use only, not for human or veterinary use. Tirzepatide / LY3298176 30mg information on this page is provided for qualified B2B sourcing, documentation review, and project discussion only. The 30mg specification refers to a vial fill quantity for project discussion and is not medical advice or product-use instruction.

This page is not intended for retail sale to individuals or individual product-use guidance. WUMO Peptide does not provide medical guidance, disease-related claims, product-use instructions, end-user recommendations, or end-user outcome claims. Final use, importation, registration, labeling, and local market compliance are the buyer responsibility.

All technical information is subject to batch-specific COA and project confirmation.

Specification and documentation references

Before requesting a quotation, these guides cover the specification and document questions that come up most often on this product.

• Tirzepatide 30mg quotation checklist — documentation, MOQ and packaging scope.
• What a 10mg vial actually contains — how peptide content, counterion, moisture and excipients divide up the mass, and what a per-vial claim needs behind it.
• Lyophilized cake appearance and reconstitution — why cakes hold or collapse, what the excipient system does, and what can reasonably be specified.